COMMUNIQUÉS West-GlobeNewswire

Altamira Announces Notice of Allowance from USPTO for Bentrio Nasal Spray Patent
07/03/2025
Hamilton, March 07, 2025 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (OTCQB:CYTOF) today announced that the U.S. Patent and Trademark Office ("USPTO") has issued a Notice of Allowance for a patent (application #17/ [...]
Avacta Announces Agreement to Sell Launch Diagnostics and a Corporate Update
07/03/2025
LONDON AND PHILADELPHIA, March 07, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, ‘the Company’), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor [...]
PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer
07/03/2025
First-ever HPV16-positive head and neck cancer Phase 3 clinical trial PRINCETON, N.J., March 07, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage [...]
ICU Medical to Participate at the KeyBanc Healthcare Forum
07/03/2025
SAN CLEMENTE, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- ICU Medical (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will [...]
COEPTIS’ NexGenAI Affiliates Partners with NUBURU Network to Drive Innovation in AI and Robotics as Part of its Transformation Plan
07/03/2025
Leveraging Advanced AI and Robotics to Revolutionize Marketing Strategies in Defense and Security Sectors WEXFORD, Pa., March 07, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (Nasdaq: COEP) ("the Company" or "COEPTIS"), a [...]
ACARIZAX® approved in Canada for treatment of young children
07/03/2025
ALK ( ALKB:DC / OMX: ALK B ) today announced that Health Canada has approved ALK’s ACARIZAX ® tablet for use in children, aged five to 11, with house dust mite (HDM) allergy. ACARIZAX ® is now indicated for treatment of [...]
Achieve Life Sciences to Present at the Barclays 27th Annual Global Healthcare Conference
07/03/2025
SEATTLE and VANCOUVER, British Columbia, March 07, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and [...]
Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025
07/03/2025
THE WOODLANDS, Texas, March 07, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the Leerink Partners Global Healthcare [...]
Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting
07/03/2025
Half-life in non-human primates (NHP) of more than 30 days, over three times longer than bimekizumab and expected to support a dose interval of two to three times per year Equivalent potency to bimekizumab with similar [...]
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
07/03/2025
DALLAS, March 07, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) ("Taysha" or the "Company"), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene [...]
Raw Garden Introduces Sprout™ Vape, Pioneering Terpene-Safe Plastic for Cannabis Hardware
06/03/2025
California’s leading cannabis extract company finds a cleaner alternative to commonly used plastic for vape hardware after testing reveals potential health risks SANTA BARBARA, Calif., March 06, 2025 (GLOBE NEWSWIRE [...]
Globus Medical to feature ExcelsiusFlex™ for Total Knee Arthroplasty at the American Academy of Orthopedic Surgeons Annual Meeting
06/03/2025
AUDUBON, Pa., March 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced it will participate in the 2025 Annual Meeting of the American Academy of [...]
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
06/03/2025
Completed enrollment of 5,000 subject Phase 2b NAVIGATE trial Severe flu season enables potential mid-year assessment of efficacy Closed $105.0 million financing with new and existing investors Significantly expanded [...]
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
06/03/2025
(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 06 mars 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 Date Nombre total d’actions composant le [...]
Monthly information on share capital and company voting rights
06/03/2025
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, March 06, 2025 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the [...]
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2024 Financial Results on March 10, 2025
06/03/2025
RESEARCH TRIANGLE PARK, N.C., March 06, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release [...]
Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
06/03/2025
- Duchenne : Reported positive initial data from INSPIRE DUCHENNE trial of next-generation Duchenne gene therapy candidate, SGT-003; In mid-2025, Company plans to request a U.S. Food and Drug Administration (FDA) [...]
CooperCompanies Announces First Quarter 2025 Results
06/03/2025
SAN RAMON, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal first quarter ended January 31, 2025. [...]
Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting
06/03/2025
BOSTON and LONDON, March 06, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for [...]

Pages